Home › Funds › Elmind Capital, LP › SNDX
Elmind Capital, LP position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
Elmind Capital, LP reported holding 1,855,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$40.6M, representing 10.19% of its reported portfolio and ranking #2 among its reported holdings. Elmind Capital, LP has disclosed SNDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's SNDX position evolved
Elmind Capital, LP first disclosed a stake in SNDX in Q4 2025 at 1,855,000 shares (US$39.0M). The position peaked in Q1 2026 at 1,855,000 shares, worth US$43.3M. Across 3 filings, Elmind Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,855,000 shares valued at US$40.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.85M | $38.97M | New |
| Q1 2026 | 1.85M | $43.33M | Hold |
| Q2 2026 | 1.85M | $40.55M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $28.79M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.01M sh · $22.18M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held SNDX?
Elmind Capital, LP has disclosed SNDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in SNDX?
As of Q2 2026, Elmind Capital, LP holds 1.85M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $40.55M, representing 10.19% of its reported portfolio and ranking #2.
Has Elmind Capital, LP been buying or selling SNDX?
In the latest 13F filing (Q2 2026), Elmind Capital, LP held unchanged its position in SNDX. The position peaked in Q1 2026 at 1.85M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.